Core Viewpoint - Becton, Dickinson and Company (NYSE:BDX) is recognized as one of the 13 cheapest Dividend Aristocrats to invest in, indicating its strong dividend history and potential value in the market [1]. Financial Performance - For fiscal Q1 2026, the company reported revenue of $5.3 billion, reflecting a 0.4% overall growth and a 2.5% growth within the New BD segment [4]. - Adjusted gross margin increased to 53.4%, and adjusted EPS was reported at $2.91, both exceeding internal forecasts [4]. Strategic Developments - The company is set to finalize the combination of its Life Sciences unit with Waters Corporation through a Reverse Morris Trust transaction, which is expected to generate a $4 billion cash distribution [5]. - Of the $4 billion, $2 billion is earmarked for share repurchases and the remaining $2 billion for debt reduction, aligning with BD's focused capital allocation strategy [5]. - CEO Thomas Polen introduced a strategic agenda called "Excellence Unleashed," aimed at enhancing competitiveness, accelerating innovation, and ensuring consistent execution [6]. Leadership Changes - During the earnings call, CEO Thomas Polen announced Shawn Bevec as the new Senior Vice President of Investor Relations, indicating a focus on strengthening investor communications [3]. Market Position - Becton, Dickinson operates as a global medical technology company, providing medical supplies, devices, laboratory equipment, and diagnostic products to various healthcare sectors [7].

Core Insights - Becton, Dickinson and Company (BD) reported stronger than expected first fiscal quarter 2026 results, highlighting the completion of its Life Sciences business combination with Waters through a Reverse Morris Trust transaction [2] Quarterly Results - BD posted total revenue of $5.3 billion, reflecting a 0.4% year-over-year increase on an FX-neutral basis; "new BD" grew 2.5% with broad-based growth across most of the portfolio, partially offset by challenges in approximately 10% of the business, including Alaris, vaccines in China, and market dynamics in China [3] - The quarter demonstrated "disciplined execution" with accelerated commercial initiatives and strength in several growth platforms, including double-digit growth in biologic drug delivery, PureWick, advanced tissue regeneration, pharmacy automation, and high single-digit growth in advanced patient monitoring [3] Profitability - BD reported an adjusted gross margin of 53.4% and adjusted EPS of $2.91, both exceeding management's expectations; however, adjusted EPS was down 15.2% year-over-year, primarily due to tariffs [4] Segment Performance - Growth was led by Connected Care and Interventional, with details provided on performance across the company's recast segment structure, which includes Medical Essentials, Connected Care, Biopharma Systems, Interventional, and Life Sciences [5] Transaction and Financial Strategy - BD closed the Waters transaction, receiving a $4 billion cash distribution, which will be allocated as $2 billion for accelerated share repurchases and $2 billion to pay down debt; net leverage ended the quarter at 2.9x, with a long-term target of 2.5x [6] - Management maintained fiscal 2026 guidance for low single-digit revenue growth and adjusted EPS of $12.35 to $12.65, while cautioning about ongoing headwinds from China, vaccines, Alaris, and a multi-hundred-basis-point tariff impact [6]

Core Insights - The company reported a revenue of $5.3 billion for Q1, reflecting a 0.4% increase, with New Becton, Dickinson and Company growing by 2.5% due to broad-based growth across key markets [2][16] - The adjusted gross margin was 53.4%, and adjusted EPS was $2.91, both exceeding expectations due to strong revenue performance and operational execution [1][20] - The company is closing a significant transaction with Waters, which is expected to unlock substantial value for shareholders, including a $4 billion cash distribution [5][21] Financial Performance - The adjusted operating margin was 21.2%, down 240 basis points year-over-year, primarily due to tariffs and increased commercial investments [20] - Free cash flow for the quarter was $548 million, with a conversion rate improving to 66% from 59% in the prior year [20] - The company returned approximately $550 million to shareholders, including dividends and share buybacks [20] Business Segments and Growth - The new segment structure includes Medical Essentials, Connected Care, Biopharma Systems, Interventional, and Life Sciences, with financials recast to reflect this reorganization [3] - The Connected Care segment, particularly APM, saw high single-digit growth, while Pharmacy Automation experienced double-digit growth [17][18] - Biopharma Systems reported low single-digit growth, with double-digit growth in biologics, offset by lower demand for vaccine products [18] Strategic Initiatives - The company is focused on enhancing its capital allocation strategy, prioritizing share repurchases, dividends, and targeted tuck-in M&A to increase return on invested capital [6] - The company has identified three key trends shaping healthcare: the rise of smart connected devices, the shift towards lower-cost care settings, and the growth in technologies addressing chronic diseases [7] - The company aims to improve operational excellence through a simplified manufacturing network, reducing global sites by nearly half [15][42] Innovation and Market Position - The company has built multiple growth platforms, each with billion-dollar potential, positioning itself at the center of key healthcare trends [8] - The innovation pipeline has been strengthened with a reallocation of $50 million towards high-growth platforms, aiming to reduce development times and accelerate product launches [12][55] - The company has a strong competitive position, with over 90% of revenues driven by recurring consumables and leading positions in more than 90% of the markets served [9][10] Guidance and Future Outlook - For fiscal 2026, the company expects low single-digit revenue growth, with a positive currency impact estimated at about 120 basis points [21][22] - Adjusted EPS guidance for fiscal 2026 is set between $12.35 and $12.65, reflecting approximately 6% growth at the midpoint [22] - The company anticipates Q2 revenue growth of approximately 2%, consistent with full-year guidance assumptions [23]

Financial Data and Key Metrics Changes - Total revenue for Q1 2026 was $5.3 billion, reflecting a 0.4% increase year-on-year, with New BD growing by 2.5% [5][18] - Adjusted gross margin was 53.4%, down 140 basis points from the prior year, primarily due to tariffs [20] - Adjusted EPS was $2.91, a decrease of 15.2% year-on-year, mainly impacted by tariffs [21] - Free cash flow for the quarter was $548 million, with a conversion rate of 66%, up from 59% in the prior year [22] Business Line Data and Key Metrics Changes - Medical Essentials experienced expected order timing dynamics and volume-based procurement in China, partially offset by share gains in the US [18] - Connected Care delivered mid-single-digit growth, led by high single-digit growth in APM [18] - Biopharma Systems grew low single digits, with double-digit growth in biologics, particularly GLP-1s, offset by lower vaccine demand [19] - Interventional and surgery segments both delivered solid mid-single-digit growth, with strong performance in Advanced Tissue Regeneration [19] Market Data and Key Metrics Changes - The US market showed solid growth in the BD Vacutainer portfolio, while challenges persisted in China due to market dynamics [18] - Alaris performance was slightly ahead of expectations despite a revenue decline due to tough comparisons to the prior year [19] - The Life Sciences segment declined due to US point-of-care headwinds and market dynamics in China [20] Company Strategy and Development Direction - The company is focused on a balanced capital allocation strategy, prioritizing share repurchases and tuck-in M&A in high-growth markets [8][9] - Key trends shaping the future of healthcare include the rise of smart devices, the shift towards lower-cost care settings, and the growth in chronic disease technologies [9][10] - The company aims to enhance its commercial capabilities and operational excellence through its "Excellence Unleashed" strategy, focusing on competing, innovating, and delivering [11][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the trajectory of the business, with core growth drivers remaining intact [27] - The company anticipates low single-digit revenue growth for New BD in fiscal 2026, with a positive currency impact expected [23] - Management acknowledged known headwinds in 10% of the portfolio but emphasized strong fundamentals in the remaining 90% [33] Other Important Information - The company is set to close a significant transaction with Waters, receiving a $4 billion cash distribution, with plans to allocate $2 billion for share repurchases and $2 billion for debt paydown [8][24] - The company has reduced its manufacturing network by nearly half, enhancing operational efficiency and cost management [16][56] Q&A Session Summary Question: Guidance for Q2 revenue and EPS - Management indicated that Q2 guidance reflects modest timing benefits and that core growth drivers remain intact, with no ramp expected from Q1 to Q2 [27][28] Question: Structural changes affecting mid-single-digit growth - Management confirmed confidence in the portfolio, noting strong performance in high-growth areas despite known headwinds [33] Question: Impact of Alaris and vaccines in China - Management expects Alaris to step up in 2027, with vaccines anticipated to have a smaller revenue impact moving forward [40][42] Question: M&A opportunities under New BD strategy - The company remains focused on tuck-in M&A that is accretive to revenue and EPS, with a robust pipeline in high-growth sectors [78][80] Question: Pricing environment and potential for price premiums - Management noted a stable pricing environment with slight positive pricing expected outside of China, anticipating improvements as VBP dynamics lessen [91]

Financial Data and Key Metrics Changes - Total revenue for Q1 2026 was $5.3 billion, reflecting a 0.4% increase year-on-year, with new BD growing by 2.5% [5][18] - Adjusted gross margin was 53.4%, down 140 basis points from the previous year, primarily due to tariffs [20] - Adjusted EPS was $2.91, a decrease of 15.2% year-on-year, driven mainly by tariff impacts [21] - Free cash flow for the quarter was $548 million, with a conversion rate of 66%, up from 59% in the prior year [22] Business Line Data and Key Metrics Changes - Medical Essentials experienced mixed performance, with expected order timing dynamics affecting MDS, but continued share gains in the US vascular access management portfolio [18] - Connected Care delivered mid-single-digit growth, led by APM, which grew high single digits [18] - Biopharma Systems grew low single digits, with double-digit growth in biologics, particularly GLP-1s, offset by lower vaccine demand [19] - Interventional and surgery segments both delivered solid mid-single-digit growth, with advanced tissue regeneration and infection prevention portfolios performing well [19] Market Data and Key Metrics Changes - Growth in China was impacted by volume-based procurement (VBP) and market dynamics, but overall volume growth was positive despite price compression [42] - The US market showed strong performance in several categories, including pharmacy automation, which grew double digits [61] Company Strategy and Development Direction - The company is focused on a balanced capital allocation strategy, prioritizing share repurchases, dividends, and targeted tuck-in M&A in high-growth markets [8][80] - The strategic priorities include competing, innovating, and delivering, with significant investments in commercial capabilities and R&D to drive growth [11][73] - The company aims to leverage trends in healthcare, such as the rise of smart devices and the shift towards lower-cost care settings, to position itself for future growth [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the trajectory of the business, maintaining a prudent approach to guidance for fiscal 2026, with expectations of low single-digit revenue growth [24][25] - The company anticipates that pricing dynamics will improve as VBP in China abates, potentially leading to positive pricing in the future [91] Other Important Information - The completion of the life sciences transaction with Waters is seen as a significant milestone, providing a $4 billion cash distribution, with plans for $2 billion in share repurchases and $2 billion for debt paydown [8][24] - The company has reduced its manufacturing network by nearly half, which is expected to lower costs and improve operational efficiency [16][56] Q&A Session Summary Question: Guidance for Q2 revenue and EPS - Management indicated that Q2 guidance reflects modest timing benefits and that core growth drivers remain intact, with no significant changes expected [27][28] Question: Structural changes affecting mid-single-digit growth - Management confirmed that the fundamentals across the majority of the portfolio remain strong, with ongoing investments in high-growth areas [33][34] Question: Impact of Alaris and vaccines in China - Management expects Alaris to improve in 2027, with vaccines anticipated to be a smaller portion of revenue moving forward [40][42] Question: Pricing environment and innovation impact - Management noted a stable pricing environment with slight positive pricing outside of China, and expects new product innovations to help drive pricing and organic revenue growth [91]

Financial Data and Key Metrics Changes - Total revenue for Q1 2026 was $5.3 billion, reflecting a 0.4% increase year-on-year, with new BD growing by 2.5% [4][15] - Adjusted gross margin was 53.4%, down 140 basis points from the previous year, primarily due to tariffs [17] - Adjusted EPS was $2.91, a decrease of 15.2% year-on-year, driven mainly by the impact of tariffs [17][20] - Free cash flow for the quarter was $548 million, with a conversion rate of 66%, up from 59% in the prior year [18] Business Line Data and Key Metrics Changes - Medical Essentials saw mixed performance, with expected order timing dynamics affecting MDS, but continued share gains in the US vascular access management portfolio [15] - Connected Care delivered mid-single-digit growth, led by APM with high single-digit growth [15] - Biopharma Systems grew low single digits, with double-digit growth in biologics, particularly GLP-1s, offset by lower vaccine demand [16] - Interventional business experienced solid mid-single-digit growth, driven by high single-digit growth in UCC and double-digit growth in PureWick [16] Market Data and Key Metrics Changes - Growth was pressured by market dynamics in China, particularly in the life sciences segment, which declined due to headwinds in US point-of-care and difficult comparisons from the prior year [17] - The company expects the value-based procurement (VBP) in China to impact 80% of its portfolio by the end of 2026, with a projected headwind of about 250 basis points for the full year [36] Company Strategy and Development Direction - The company is focused on a balanced capital allocation strategy, prioritizing share repurchases and tuck-in M&A in high-growth markets [6][73] - The transformation into a pure-play med tech company is supported by divesting non-core assets and enhancing its portfolio through strategic acquisitions [7] - The company identified three key trends shaping healthcare: the rise of smart devices, the shift towards lower-cost care settings, and the growth in technologies addressing chronic diseases [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the trajectory of the business, maintaining a prudent approach to guidance for fiscal 2026, expecting low single-digit revenue growth [20] - The company anticipates that pricing dynamics will improve as VBP in China abates, potentially leading to positive pricing in the future [85] - Management highlighted strong execution in commercial initiatives and a robust innovation pipeline, which are expected to drive future growth [9][68] Other Important Information - The company completed a significant transaction with Waters, receiving a $4 billion cash distribution, with plans to allocate $2 billion for share repurchases and $2 billion for debt paydown [6][19] - The company has reduced its manufacturing network by nearly half, which is expected to lower costs and improve operational efficiency [13][50] Q&A Session Summary Question: Guidance for Q2 revenue and EPS - Management confirmed that Q2 guidance reflects modest timing benefits and remains aligned with Q1 performance, with no fundamental changes expected [23][44] Question: Structural changes affecting mid-single-digit growth - Management reassured that the fundamentals across the majority of the portfolio remain strong, with continued investment in high-growth areas [28] Question: Impact of Alaris and vaccines in China - Management indicated that Alaris is expected to improve in 2027, while vaccine impacts are anticipated to lessen over time [36][71] Question: Pricing environment and innovation impact - Management noted a stable pricing environment with slight positive trends expected, particularly as new product innovations are introduced [84][85]

Core Insights - Becton, Dickinson and Company (BDX) met Wall Street's revenue expectations for Q3 CY2025, achieving sales of $5.89 billion, reflecting an 8.3% year-on-year growth [1][3] - The company's non-GAAP profit was $3.96 per share, exceeding analysts' consensus estimates by 1.2% [1][6] - Management highlighted strong demand in Interventional, Biologics, and Advanced Patient Monitoring segments as key drivers of organic growth, despite challenges in vaccine demand and research funding [3][5] Financial Performance - Revenue for Q3 was $5.89 billion, slightly below analyst estimates of $5.91 billion, but still showing an 8.3% year-on-year growth [6] - Adjusted EPS was $3.96, beating analyst estimates of $3.91 by 1.2% [6] - Adjusted EBITDA stood at $1.78 billion, maintaining a 30.2% margin, in line with expectations [6] - Operating margin was reported at 11.8%, consistent with the same quarter last year [6] - Market capitalization reached $50.84 billion [6] Future Outlook - The company is adopting a cautious approach to ongoing headwinds in vaccines, China, and the Alaris pump segment, focusing on reallocating resources to high-growth and high-margin areas [4] - CEO Thomas Polen indicated plans for mid-single-digit growth in 90% of the portfolio unaffected by current macro pressures, alongside investments in commercial and innovation initiatives [4] - A $200 million cost reduction program is being executed, with a focus on internal investment and share repurchases [4]

Core Insights - Becton Dickinson and Co (BDX) reported fourth-quarter adjusted earnings of $3.96, surpassing the consensus estimate of $3.92 [1] - The company is facing challenges, with third-quarter 2025 sales of $5.89 billion, slightly below the consensus of $5.90 billion, but revenues increased by 8.3% as reported [2] Financial Performance - Medical segment sales rose by 11.2% to $3.16 billion, with a 4% organic growth [3] - Life Sciences sales reached $1.37 billion, up 2.1% [5] - Interventional sales increased by 8.5% to $1.37 billion [6] - The company declared a quarterly dividend of $1.05 per share, marking a 1.0% increase [9] Segment Analysis - Medication Delivery Solutions showed strong growth, particularly in Vascular Access Management, despite some volume-based procurement challenges in China [3] - Pharmaceutical Systems experienced high single-digit growth in Biologics, offset by lower vaccine demand, with notable performance from the HemoSphere Alta Monitor and Acumen IQ sensors [4] - Surgery segment reported double-digit growth in Advanced Tissue Regeneration and Biosurgery, while Urology and Critical Care saw strong growth in the PureWick franchise [7][8] Guidance and Future Outlook - For fiscal 2026, BDX expects adjusted earnings between $14.75 and $15.05 per share, above the consensus of $14.38, with low single-digit revenue growth anticipated [10] - The company expects first-quarter revenue growth to decline in low single digits, with adjusted earnings projected between $2.75 and $2.85 [10] - BDX plans to use at least half of the $4 billion cash distribution from the Waters RMT transaction for share repurchases [12] Strategic Developments - In July, BDX announced a merger of its Biosciences & Diagnostic Solutions business with Waters Corp, valued at approximately $17.5 billion, expected to close by the end of Q1 2026 [11]

Financial Data and Key Metrics Changes - Q4 revenue reached $5.9 billion, representing a 7% increase and 3.9% organic growth, while full-year revenue was a record $21.8 billion, up 7.7% and 2.9% organic [4][5] - Adjusted diluted EPS for Q4 was $3.96, with a full-year record of $14.40, reflecting a 9.6% growth, including a two-point impact from tariffs [5][17] - Adjusted gross margin for Q4 was 54.2%, and adjusted operating margin was 25.8%, with a full-year adjusted gross margin of 54.7% and operating margin of 25% [16][17] Business Line Data and Key Metrics Changes - New BD achieved strong organic growth of 4.9% in Q4, with significant contributions from various segments [4] - BD Interventional experienced high single-digit growth, driven by double-digit growth in PureWick and advanced tissue regeneration [7][14] - Pharma systems saw high single-digit growth in biologics, offset by lower vaccine demand, which constitutes about 20% of pharma systems revenue [15][23] Market Data and Key Metrics Changes - The biosciences business showed sequential improvement in sales in the U.S. and EMEA, led by demand for the new FACSDiscover platform [7][15] - Research funding in biosciences remained subdued, impacting growth, while diagnostic solutions returned to positive growth due to recovering BD BACTEC utilization [7][15] - China is expected to decline in the mid-teens due to government policies, impacting growth by about 100 basis points [23][51] Company Strategy and Development Direction - The company is focused on accelerating its strategy as it transitions into new BD, emphasizing commercial excellence and innovation [10][20] - A two-year $200 million cost-out program has been initiated to address stranded corporate costs, with approximately half expected this year [12] - The company plans to enhance its capital allocation strategy, prioritizing internal investment, share repurchases, and a reliable dividend [21][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in long-term mid-single digit growth despite transitory market dynamics expected to continue into fiscal 2026 [9][24] - The company is taking a prudent approach to guidance, incorporating updated views on the operating environment, particularly regarding vaccines and China [31][32] - Management highlighted the importance of BD Excellence in driving margin expansion and cash generation, with expectations for continued strong performance [20][56] Other Important Information - The company announced its 54th consecutive year of dividend increases and returned $2.2 billion to shareholders, including a $1 billion share buyback [5][17] - The Waters transaction is seen as a significant strategic opportunity to unlock value for investors, with expected closure around the end of Q1 2026 [18][27] Q&A Session All Questions and Answers Question: How does the guidance for new BD reflect conservatism? - Management emphasized a prudent approach to guidance, incorporating macro dynamics and not assuming improvements in the operating environment [31][32] Question: What are the expectations for Q1 compared to the full year? - Q1 guidance reflects full-year headwinds, with expectations for growth to step up in Q2 and Q3, which are anticipated to be the strongest quarters [36][37] Question: Why not be more aggressive in returning capital to shareholders? - Management stated the focus remains on cash generation and disciplined capital allocation, with plans for significant share buybacks post-Waters transaction [41][42] Question: What was the organic growth in China for Q4? - China experienced high single-digit organic growth in Q4, with a cautious outlook due to volume-based procurement policies [51] Question: Can new BD grow EPS double digits? - Management expressed confidence in the new BD's ability to achieve high single-digit EPS growth, supported by strong cash generation and margin expansion [55][56]

Financial Data and Key Metrics Changes - Q4 revenue reached $5.9 billion, an increase of 7% and 3.9% organic growth, while full-year revenue was a record $21.8 billion, up 7.7% and 2.9% organic [4][5] - Adjusted diluted EPS for Q4 was $3.96, with a full-year record of $14.40, representing a 9.6% growth, including a two-point impact from tariffs [5][18] - Adjusted gross margin for Q4 was 54.2%, and adjusted operating margin was 25.8%, with a year-over-year increase of 140 and 80 basis points respectively [17][18] Business Line Data and Key Metrics Changes - BD Interventional experienced high single-digit growth, driven by double-digit growth in PureWick and advanced tissue regeneration [7][15] - Pharma systems saw high single-digit growth in biologics, but lower demand for vaccine products impacted overall performance [16] - The biosciences and diagnostic solutions segments returned to positive growth, with a significant improvement in BD BACTEC utilization [16][17] Market Data and Key Metrics Changes - Research funding in the biosciences business remained subdued, but sales in the U.S. and EMEA improved sequentially [7][16] - The China market is expected to decline in the mid-teens due to government policies, impacting growth by about 100 basis points [23][50] - Vaccines, which account for approximately 20% of pharma systems revenue, are projected to decline by about 25%, impacting growth by approximately 50 basis points [23] Company Strategy and Development Direction - The company is focused on creating a more agile, vertical organization to enhance commercial excellence and drive growth [10][76] - A two-year $200 million cost-out program has been initiated to address stranded corporate costs, with approximately half expected this year [12] - The company aims to deliver consistent mid-single digit revenue growth over the long term, supported by a strong innovation pipeline and BD Excellence initiatives [21][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term mid-single digit growth profile despite transitory market dynamics [9][24] - The company is taking a prudent approach to guidance, incorporating updated views on the operating environment and specific portfolio areas [30][31] - The upcoming combination with Waters is seen as a significant strategic opportunity to unlock value for investors [19][28] Other Important Information - The company returned $2.2 billion to shareholders, including a $1 billion share buyback, and announced its 54th consecutive year of dividend increases [5][18] - The adjusted effective tax rate is expected to be between 14% and 15% [25] Q&A Session Summary Question: How does the guidance for new BD reflect conservatism? - Management emphasized a prudent approach to guidance, incorporating macro dynamics and specific portfolio areas, while maintaining confidence in growth [30][31] Question: What are the implications of the Q1 guide versus the full year? - The Q1 guide reflects full-year headwinds, with expectations for growth to step up in Q2 and Q3 [34][35] Question: Why not be more aggressive in returning capital to shareholders? - The focus remains on cash generation and disciplined capital allocation, with plans for significant share buybacks post-Waters transaction [39][40] Question: What is the expectation for China market performance? - The company anticipates a mid-teens decline in China, with a prudent approach to future guidance [50] Question: Can new BD grow EPS double digits? - Management is confident in the potential for double-digit EPS growth driven by strong cash generation and margin expansion [52][56]